Medication use in early pregnancy-prevalence and determinants of use in a prospective cohort of women

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 4, 2010, Pages 408-417

  Cleary, Brian J ^a,b,c   Butt, Hajeera ^b   Strawbridge, Judith D ^c   Gallagher, Paul J ^c   Fahey, Tom ^c   Murphy, Deirdre J ^a,b  

^a Molecular Pathology Laboratory   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

FDA; Medication; Pregnancy; Prevalence; Safety; Teratogen

Indexed keywords

HERBACEOUS AGENT; ILLICIT DRUG; NON PRESCRIPTION DRUG;

ARTICLE; ASTHMA; COHORT ANALYSIS; DEPRESSION; DRUG CLASSIFICATION; DRUG UTILIZATION; EXPOSURE; FEMALE; FETUS RISK; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; GESTATIONAL AGE; HUMAN; INTERVIEW; IRELAND; MAJOR CLINICAL STUDY; MATERNAL SMOKING; MATERNITY WARD; MEDICAL RECORD REVIEW; MIDWIFE; NULLIPARA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; UNEMPLOYMENT; UNWANTED PREGNANCY;

ADULT; COHORT STUDIES; DRUG UTILIZATION REVIEW; FEMALE; FETAL DEVELOPMENT; GESTATIONAL AGE; HUMANS; PHARMACEUTICAL PREPARATIONS; PLANT PREPARATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; PRESCRIPTION DRUGS; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; STREET DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 77950872913     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1906     Document Type: Article

References (42)

1. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002; 100(3): 465-473.
2. Enriquez R, Griffin MR, Carroll KN, et al. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. J Allergy Clin Immunol 2007; 120(3): 625-630. (Pubitemid 47320762)
3. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer- 2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. In: Lewis G, (ed.). London: CEMACH, 2007.
4. National Perinatal Reporting System. Report on Perinatal Statistics for 2004. Dublin: ESRI, 2007.
5. Centre for Epidemiology. Registration of congenital malformations 2005. Stockholm: National Board of Health, Available from: http://www.socialstyrelsen. se/Publicerat/2006/9375/Summary.htm, Accessed [22nd December 2008].
6. Bewley S, Ledger W, Nikolaou D. Reproductive Ageing. RCOG Press: London, 2009.
7. Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38(2): 90-96.
8. Food and Drug Administration. Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. In: Federal Register, editor: Health and Human Services, 2008; 30831-30868.
9. Public Affairs Committee of the Teratology Society. Teratology public affairs committee position paper: pregnancy labeling for prescription drugs: Ten years later. Birth Defects Res A Clin Mol Teratol 2007; 79(9): 627-630.
10. Headley J, Northstone K, Simmons H, Golding J. Medication use during pregnancy: data from the Avon longitudinal study of parents and children. Eur J Clin Pharmacol 2004; 60(5): 355-361. (Pubitemid 39062322)
11. Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81 975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15(8): 555-564.
12. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet 2000; 356(9243): 1735-1736.
13. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191(2): 398-407.
14. Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008; 65(5): 653-660. (Pubitemid 351535090)
15. Hernández-Díaz S. Prescription of medications during pregnancy: accidents, compromises, and uncertainties. Pharmacoepidemiology and Drug Safety 2006; 15(9): 613-617. (Pubitemid 44404657)
16. Sannerstedt R, Lundborg P, Danielsson BR, et al. Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 1996; 14(2): 69-77. (Pubitemid 26048402)
17. Briggs GG. Drugs in Pregnancy and Lactation (8th edn) Lippincott Williams & Wilkins: Philadelphia, 2008.
18. Scottish Intercollegiate Guideline Network. British Guideline on the Management of Asthma. Edinburgh: SIGN, 2008.
19. Busse WW. NAEPP expert panel report: managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 Update. J Allergy Clin Immunol 2005; 115(1): 34-46.
20. National Collaborating Centre for Mental Health. Antenatal and Post-natal Mental Health- The NICE Guideline on Clinical Management and Service Guidance. The British Psychological Society & The Royal College of Psychiatrists: London, 2007.
21. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18(3): 139-185. (Pubitemid 38425770)
22. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995; 85(1): 141-149.
23. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008(2): CD003511.
24. Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005; 73(11): 906-918.
25. Fraser FC. Recall bias in case control studies of malformed infants. Teratology 2000; 62(6): 371.
26. Bosio P, Keenan E, Gleeson R, et al. The prevalence of chemical substance and alcohol abuse in an obstetric population in Dublin. Ir Med J 1997; 90(4): 149-150. (Pubitemid 127686483)
27. Pichini S, Puig C, Zuccaro P, et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the "Meconium Project". Forensic Sci Int 2005; 153(1): 59-65.
28. Egen-Lappe V, Hasford J. Drug prescription in pregnancy: analysis of a large statutory sickness fund population. Eur J Clin Pharmacol 2004; 60(9): 659-666. (Pubitemid 40064599)
29. Malm H, Martikainen J, Klaukka T, Neuvonen PJ. Prescription drugs during pregnancy and lactation - a Finnish register-based study. Eur J Clin Pharmacol 2003; 59(2): 127-133. (Pubitemid 36793725)
30. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113(5): 559-568.
31. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64(11): 1125-1132.
32. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006; 15(8): 546-554.
33. Yang T, Walker MC, Krewski D, et al. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 2008; 17(3): 270-277.
34. Andrade SE, Raebel MA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf 2008; 17(3): 240-247. (Pubitemid 351404035)
35. Bakker MK, Kolling P, van den Berg PB, deWalle HE, de Jong van den Berg LT. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 2008; 65(4): 600-606. (Pubitemid 351365128)
36. Olesen C, Sondergaard C, Thrane N, Nielsen GL, Berg LdJ-vd, Olsen J. Do pregnant women report use of dispensed medications? Epidemiology 2001; 12(5): 497-501.
37. Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for "pharmacological programming" in the first trimester? Hypertens Pregnancy 2002; 21(2): 161-174.
38. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006; 82(1): 23-28. (Pubitemid 43163036)
39. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354(23): 2443-2451. (Pubitemid 43855047)
40. GlaxoSmithKline. Epidemiology Study: Updated Preliminary Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation: GlaxoSmithKline, 2005.
41. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79(4): 301-308.
42. Lee E, Maneno MK, Smith L, et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006; 15(8): 537-545. (Pubitemid 44336268)